Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-11-14
2009-11-10
Aulakh, Charanjit S (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C424S001370, C546S276700
Reexamination Certificate
active
07615567
ABSTRACT:
Compounds and methods for promoting smoking cessation. The compounds may be used to treat a variety of other conditions and disease states.
REFERENCES:
patent: 3555154 (1971-01-01), Enkoji et al.
patent: 3734851 (1973-05-01), Matsumura
patent: 4242460 (1980-12-01), Chick et al.
patent: 4354933 (1982-10-01), Lester
patent: 4539143 (1985-09-01), Boden et al.
patent: 4568538 (1986-02-01), Boden et al.
patent: 4587981 (1986-05-01), Boden et al.
patent: 4677207 (1987-06-01), Boden et al.
patent: 4973493 (1990-11-01), Guire
patent: 5002582 (1991-03-01), Guire et al.
patent: 5128118 (1992-07-01), Carroll et al.
patent: 5141959 (1992-08-01), Carroll et al.
patent: 5298499 (1994-03-01), Carroll et al.
patent: 5360790 (1994-11-01), Humes
patent: 5380848 (1995-01-01), Kuhar et al.
patent: 5413779 (1995-05-01), Kuhar et al.
patent: 5414075 (1995-05-01), Swan et al.
patent: 5429938 (1995-07-01), Humes
patent: 5437994 (1995-08-01), Emerson et al.
patent: 5459069 (1995-10-01), Palsson et al.
patent: 5496953 (1996-03-01), Kuhar et al.
patent: 5499976 (1996-03-01), Dalton
patent: 5516680 (1996-05-01), Naughton et al.
patent: 5549674 (1996-08-01), Humes et al.
patent: 5550050 (1996-08-01), Holland et al.
patent: 5565573 (1996-10-01), Larock
patent: 5580697 (1996-12-01), Keana et al.
patent: 5605822 (1997-02-01), Emerson et al.
patent: 5639275 (1997-06-01), Baetge et al.
patent: 5653975 (1997-08-01), Baetge et al.
patent: 5656481 (1997-08-01), Baetge et al.
patent: 5661133 (1997-08-01), Leiden et al.
patent: 5676943 (1997-10-01), Baetge et al.
patent: 5686289 (1997-11-01), Humes et al.
patent: 5733727 (1998-03-01), Field
patent: 5736123 (1998-04-01), Carroll
patent: 5763266 (1998-06-01), Palsson et al.
patent: 5773286 (1998-06-01), Dionne et al.
patent: 5795790 (1998-08-01), Schinstine et al.
patent: 5817679 (1998-10-01), Shen et al.
patent: 5831095 (1998-11-01), Gonzalez et al.
patent: 5833978 (1998-11-01), Tremblay
patent: 5843781 (1998-12-01), Ballermann et al.
patent: 5858653 (1999-01-01), Duran et al.
patent: 5906817 (1999-05-01), Moullier et al.
patent: 5919449 (1999-07-01), Dinsmore
patent: 5935953 (1999-08-01), Kuhar et al.
patent: 5965125 (1999-10-01), Mineau-Hanschke
patent: 6060270 (2000-05-01), Humes
patent: 6110209 (2000-08-01), Stone
patent: 6123917 (2000-09-01), Carroll
patent: 6150164 (2000-11-01), Humes
patent: 6156304 (2000-12-01), Glorioso et al.
patent: 6177451 (2001-01-01), Qian et al.
patent: 6329520 (2001-12-01), Carroll et al.
patent: 6358492 (2002-03-01), Kuhar et al.
patent: 6416735 (2002-07-01), Carroll et al.
patent: 6479509 (2002-11-01), Carroll
patent: 6531481 (2003-03-01), Carroll et al.
patent: 6531483 (2003-03-01), Kuhar et al.
patent: 6538010 (2003-03-01), Carroll
patent: 6552032 (2003-04-01), Carroll et al.
patent: 6559159 (2003-05-01), Carroll et al.
patent: 6593348 (2003-07-01), Carroll et al.
patent: 6706880 (2004-03-01), Carroll et al.
patent: 6900228 (2005-05-01), Carroll et al.
patent: 2002/0132828 (2002-09-01), Carroll et al.
patent: 2002/0188003 (2002-12-01), Kuhar et al.
patent: 2003/0158415 (2003-08-01), Carroll et al.
patent: 2003/0176434 (2003-09-01), Carroll
patent: 2003/0203934 (2003-10-01), Kuhar et al.
patent: 2004/0146518 (2004-07-01), Carroll et al.
patent: 2005/0197360 (2005-09-01), Kuhar et al.
patent: 0 154 844 (1985-09-01), None
patent: 0 955 301 (1999-11-01), None
patent: 1 479 002 (1974-06-01), None
patent: 60-208961 (1985-10-01), None
patent: 07-61940 (1995-03-01), None
patent: 11-501282 (1999-02-01), None
patent: 11-322751 (1999-11-01), None
patent: WO 89/01967 (1989-03-01), None
patent: W0 91/00119 (1991-01-01), None
patent: WO 92/07615 (1992-05-01), None
patent: WO 93/17696 (1993-09-01), None
patent: WO 95/07078 (1995-03-01), None
patent: WO 96/06093 (1996-02-01), None
patent: WO 01/44243 (2001-06-01), None
W. Glassco, et al., “Comparative Sar Studies of N-Substituted Nornicotines and N-Substituted Norbridged Nicotines”, Problems of Drug Dependence, 1994: Proceedings of the 56thAnnual Scientific Meeting, The College on Problems of Drug Dependence, Inc., vol. II: Abstracts, p. 190.
M. Damaj, et al., “Pharmacological Characterization of Nicotine's Interaction with Cocaine and Cocaine Analogs1”, The Journal of Pharmacology and Experimental Therapeutics, vol. 289, No. 3, 1999, pp. 1229-1236.
E. albertini, et al., “Enantioselective Approach to 7-Azabicyclo[2.2.1]heptane Ring systems Using D-(−)-Quinic Acid as the Chiral Educt: Application to the Formal Synthesis of (+)-Epibatidine”, Tetrahedron Letters, vol. 38, No. 4, 1997, pp. 681-684.
G. Lloyd, et al., “Neuronal Nicotinic Acetylcholine Receptors as Novel Drug Targets”, The Journal of Pharmacology and Experimental Therapeutics, vol. 292, No. 2, 2000, pp. 461-467.
D. Bai, et al., “Epibatidine”, Drugs of the Future, vol. 22, No. 11, 1997, pp. 1210-1220.
S. Singh, et al., “Efficient Synthesis of (+)-N-BOC-exo-2-(methoxycarbony1)-7-Azabicyclo[2.2.1]heptane, A Versatile Intermediate for the Synthesis of Epibatidine and Epiboxidine”, Tetrahedron Letters. vol. 38, No. 39, 1997, pp. 6829-6830.
M. Davila-Garcia, et al., “[125]IPH, An Epibatidine Analog, Binds with High Affinity to Neuronal Nicotinic Cholinergic Receptors1”, The Journal of Pharmacology and Experimental Therapeutics, vol. 282, No. 1, 1997, pp. 445-451.
I. Khan, et al., “Epibatidine Binding Sites and Activity in the Spinal Cord”, Brain Research, vol. 753, 1997, pp. 269-282.
E. Levin, et al., “Epibatidine, A Potent Nicotinic Agonist: Effects on Learning and Memory in the Radial-Arm Maze”, Medicinal Chemistry Research, 1996, pp. 543-554.
J. Sullivan, et al., “Epibatidine: Pharmacological Properties of a Novel Nicotinic Acetylcholine Receptor Agonist and Analgesic Agent”, CNS Drug Reviews, vol. 2, No. 1, 1996, pp. 21-39.
A. Horti, et al., “Synthesis of a Radiotracer for Studying Nicotinic Acetylcholine Receptors: (+/−)-exo-2-(2-[1BF]fluoro-5-pyridyl)-7-azabicyclo[2.2.1]heptane”, Journal of Labelled Compounds and Radiopharmaceuticals, vol. 38, No. 4, 355-365.
C. Zhang, et al., “A Short and Efficient Total Synthesis of (+)-Epibatidine”, Journal of Organic Chemistry, vol. 61, 1996, pp. 7189-7191.
D. Bai, et al., “Synthesis of (+)-Epibatidine and Its Analogues”, Journal of Organic Chemistry, vol. 61, 1996, pp. 4600-4606.
R. Xu, et al., “Total Synthesis of (+)Epibatidine”, Tetrahedron Letters, vol. 37, No. 9, 1996, pp. 1463-1466.
J. Musachio, et al., “Synthesis of a Radioiodinated Analog of Epibatidine: (+/−)-exo-2-(2-iodo-5-pyridy1)-7-azabicyclo[2.2.1]heptane for in vitro and in vivo Studies of Nicotinic Acetylcholine Receptors”, Journal of Labelled Compounds and Radiopharmaceuticals, vol. 39, No. 1, pp. 39-48.
A. Sacaan, et al., “Epibatidine: A Nicotinic Acetylcholine Receptor Agonist Releases Monoaminergic Neurotransmitters: In vitro and In vivo Evidence in Rats”, The Journal of Pharmacology and Experimental Therapeutics, vol. 276, No. 2, 1996, pp. 509-515.
U. Warpman, et al., “Epibatidine and ABT 418 Reveal Selective Losses of α4β2 Nicotinic Receptors in Alzheimer Brains”, NeuroReport, vol. 6, No. 17, 1995, pp. 2419-2423.
R. Xu, et al., “Synthesis and Analgesic Activity of Epibatidine Analogues”, Bioorganic and Medicinal Chemistry Letters, vol. 6, No. 3, 1996, pp. 279-282.
C. Szantay, et al., “Epibatidine”, The Alkaloids, vol. 46, 1995, pp. 95-125.
D. Perry, et al., “[3]Epibatidine Labels Nicotinic Receptors in Rat Brain: An Autoradiographic Study1”, The Journal of Pharmacology and Experimental Therapeutics, vol. 275, No. 2, 1995, pp. 1030-1034.
G. Pandey, et al., “An Expeditious Synthesis of Epibatidine and Analogues”, Tetrahedron Letters, vol. 35, No. 40, 1994, pp. 7439-7442.
V. Gerzanich, et al., “Comparative Pharmacology of Epibatidine: A Potent Agonist for Neuronal Nicotinic Acetylcholine Receptors
Aulakh Charanjit S
Oblon, Spivak McClelland, Maier & Neustadt, L.L.P.
Research Triangle Institute
LandOfFree
Compounds and methods for promoting smoking cessation does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds and methods for promoting smoking cessation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds and methods for promoting smoking cessation will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4113967